H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 101 Citations 34,431 546 World Ranking 247 National Ranking 161
Medicine D-index 123 Citations 52,534 976 World Ranking 1345 National Ranking 813

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Surgery

David M. Goldenberg mainly focuses on Antibody, Monoclonal antibody, Pathology, Radioimmunotherapy and Cancer. His Antibody research includes themes of Molecular biology, In vivo and Antigen. His research in Monoclonal antibody focuses on subjects like Pharmacology, which are connected to SN-38, Sacituzumab govitecan and Antibody-drug conjugate.

He has included themes like Pharmacokinetics, Carcinoembryonic antigen, Head and neck cancer and Metastasis in his Pathology study. His Radioimmunotherapy study incorporates themes from Gastroenterology, Nuclear medicine, Toxicity, Radiation therapy and Bone marrow. His Cancer research includes elements of Cancer research and Oncology.

His most cited work include:

  • Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning (674 citations)
  • Immunotherapy of B-cell malignancies using anti-CD22 antibodies (428 citations)
  • Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy (303 citations)

What are the main themes of his work throughout his whole career to date?

Antibody, Internal medicine, Monoclonal antibody, Pathology and Radioimmunotherapy are his primary areas of study. His biological study spans a wide range of topics, including Molecular biology, Cancer research, Antigen and Carcinoembryonic antigen. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Surgery and Oncology.

His studies deal with areas such as In vivo, Biodistribution and Pharmacology as well as Monoclonal antibody. His study of Carcinoma is a part of Pathology. David M. Goldenberg interconnects Nuclear medicine, Radiation therapy, Toxicity and Bone marrow in the investigation of issues within Radioimmunotherapy.

He most often published in these fields:

  • Antibody (24.66%)
  • Internal medicine (19.08%)
  • Monoclonal antibody (18.39%)

What were the highlights of his more recent work (between 2013-2021)?

  • Internal medicine (19.08%)
  • Cancer (15.98%)
  • Surgery (11.50%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Cancer, Surgery, Oncology and Sacituzumab govitecan. His studies in Internal medicine integrate themes in fields like Gastroenterology and Immunology. His Cancer study integrates concerns from other disciplines, such as Cancer research and Epidemiology, Pathology.

His study focuses on the intersection of Cancer research and fields such as Antibody with connections in the field of Molecular biology. His Surgery research incorporates elements of Thyroid and Thyroid cancer. Many of his studies on Oncology apply to Radioimmunotherapy as well.

Between 2013 and 2021, his most popular works were:

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. (157 citations)
  • AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER. (151 citations)
  • Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) (133 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Surgery

His main research concerns Internal medicine, Cancer, Sacituzumab govitecan, Pharmacology and Antibody-drug conjugate. His research integrates issues of Gastroenterology, Surgery and Oncology in his study of Internal medicine. The concepts of his Cancer study are interwoven with issues in Cancer research, Epidemiology and Human papillomavirus.

His Cancer research study also includes

  • Immunology which is related to area like In vivo,
  • Antigen which connect with Pathology and Immunohistochemistry. His Pathology study combines topics from a wide range of disciplines, such as Molecular imaging, Prostate cancer and Monoclonal antibody. David M. Goldenberg combines subjects such as Immune system and Immunotherapy with his study of Antibody.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

D.M. Goldenberg;F. DeLand;E. Kim;S. Bennett.
The New England Journal of Medicine (1978)

1043 Citations

Immunotherapy of B-cell malignancies using anti-CD22 antibodies

David M. Goldenberg.
(1998)

460 Citations

Targeted Therapy of Cancer with Radiolabeled Antibodies

David M Goldenberg.
The Journal of Nuclear Medicine (2002)

434 Citations

Ionization−Reactivity Relationships for Cysteine Thiols in Polypeptides†

Grzegorz Bulaj;Tanja Kortemme;David P. Goldenberg.
Biochemistry (1998)

427 Citations

Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen

D M Goldenberg;E E Kim;F H DeLand;S Bennett.
Cancer Research (1980)

386 Citations

CYSTIC LYMPH NODE METASTASIS IN PATIENTS WITH HEAD AND NECK CANCER: AN HPV-ASSOCIATED PHENOMENON

David Goldenberg;Shahnaz Begum;William H. Westra;Zubair Khan.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck (2008)

382 Citations

Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy

David M. Goldenberg;Robert M. Sharkey;Giovanni Paganelli;Jacques Barbet.
Journal of Clinical Oncology (2006)

378 Citations

Kinetic role of a meta-stable native-like two-disulphide species in the folding transition of bovine pancreatic trypsin inhibitor☆

T.E. Creighton;D.P. Goldenberg.
Journal of Molecular Biology (1984)

375 Citations

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

Thomas Dörner;Joerg Kaufmann;William A Wegener;Nick Teoh.
Arthritis Research & Therapy (2008)

357 Citations

A Novel Method of 18F Radiolabeling for PET

William J. McBride;Robert M. Sharkey;Habibe Karacay;Christopher A. D'Souza.
The Journal of Nuclear Medicine (2009)

350 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing David M. Goldenberg

Hans J. Hansen

Hans J. Hansen

Eisai (Japan)

Publications: 95

Wim J.G. Oyen

Wim J.G. Oyen

Humanitas University

Publications: 87

Oliver W. Press

Oliver W. Press

Fred Hutchinson Cancer Research Center

Publications: 83

Vladimir Tolmachev

Vladimir Tolmachev

Uppsala University

Publications: 77

Otto C. Boerman

Otto C. Boerman

Radboud University Nijmegen

Publications: 67

Jeffrey Schlom

Jeffrey Schlom

National Institutes of Health

Publications: 64

Joseph A. Califano

Joseph A. Califano

University of California, San Diego

Publications: 59

Jorge A. Carrasquillo

Jorge A. Carrasquillo

Memorial Sloan Kettering Cancer Center

Publications: 57

Anna Orlova

Anna Orlova

Uppsala University

Publications: 55

Jonathan King

Jonathan King

MIT

Publications: 55

Steven M. Larson

Steven M. Larson

Memorial Sloan Kettering Cancer Center

Publications: 50

Anna M. Wu

Anna M. Wu

City Of Hope National Medical Center

Publications: 48

George Sgouros

George Sgouros

Johns Hopkins University

Publications: 48

Andrew M. Scott

Andrew M. Scott

La Trobe University

Publications: 48

Ira Pastan

Ira Pastan

Center for Cancer Research

Publications: 47

Dario Neri

Dario Neri

École Polytechnique Fédérale de Lausanne

Publications: 44

Something went wrong. Please try again later.